[{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Entecavir","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"Replicor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Peginterferon Alfa-2a","moa":"||HBV RNA","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Replicor","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Replicor \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Replicor \/ Inapplicable"},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ATI-2173","moa":"||Active site polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Antios Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Antios Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antios Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Emtricitabine","moa":"||HIV-1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Emtricitabine","moa":"||HIV-1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Emtricitabine","moa":"||HIV-1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Emtricitabine","moa":"||HIV-1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Yung Shin Pharm Industrial","sponsor":"Taichung Veterans General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"TAIWAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tenofovir Disoproxil Fumarate","moa":"||Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Yung Shin Pharm Industrial","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Yung Shin Pharm Industrial \/ Taichung Veterans General Hospital","highestDevelopmentStatusID":"11","companyTruncated":"Yung Shin Pharm Industrial \/ Taichung Veterans General Hospital"},{"orgOrder":0,"company":"Guy's and St Thomas' NHS Foundation Trust","sponsor":"ViiV Healthcare | Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Maraviroc","moa":"||C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Guy's and St Thomas' NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Guy's and St Thomas' NHS Foundation Trust \/ ViiV Healthcare | Gilead Sciences","highestDevelopmentStatusID":"11","companyTruncated":"Guy's and St Thomas' NHS Foundation Trust \/ ViiV Healthcare | Gilead Sciences"},{"orgOrder":0,"company":"Samjin pharm Co. Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tenofovir Disoproxil Fumarate","moa":"||Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Samjin pharm Co. Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Samjin pharm Co. Ltd \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Samjin pharm Co. Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Samjin pharm Co. Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tenofovir Disoproxil Fumarate","moa":"||Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Samjin pharm Co. Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Samjin pharm Co. Ltd \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Samjin pharm Co. Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tenofovir Disoproxil Fumarate","moa":"||Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viatris \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Viatris \/ Inapplicable"},{"orgOrder":0,"company":"Brigham and Women's Hospital","sponsor":"Gilead Sciences | The Fenway Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Emtricitabine","moa":"||Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Brigham and Women's Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Brigham and Women's Hospital \/ Gilead Sciences | The Fenway Institute","highestDevelopmentStatusID":"11","companyTruncated":"Brigham and Women's Hospital \/ Gilead Sciences | The Fenway Institute"},{"orgOrder":0,"company":"Henan Genuine Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Azvudine","moa":"||Replicase polyprotein 1ab | Reverse transcriptase | Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Henan Genuine Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Henan Genuine Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Henan Genuine Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Plan Nacional sobre el Sida","sponsor":"Effice Servicios Para la Investigacion","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Emtricitabine","moa":"||Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Plan Nacional sobre el Sida","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Plan Nacional sobre el Sida \/ Effice Servicios Para la Investigacion","highestDevelopmentStatusID":"10","companyTruncated":"Plan Nacional sobre el Sida \/ Effice Servicios Para la Investigacion"},{"orgOrder":0,"company":"Xi'an Xintong Pharmaceutical Research Co.,Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pradefovir Mesylate","moa":"||DNA polymerase\/reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Xi'an Xintong Pharmaceutical Research Co.,Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Xi'an Xintong Pharmaceutical Research Co.,Ltd. \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xi'an Xintong Pharmaceutical Research Co.,Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"||Structural capsid protein","graph1":"Undisclosed","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ANRS, Emerging Infectious Diseases","sponsor":"Merck & Co | European & Developing Countries Clinical Trials Partnership","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Doravirine","moa":"||Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ANRS, Emerging Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"ANRS, Emerging Infectious Diseases \/ Merck & Co | European & Developing Countries Clinical Trials Partnership","highestDevelopmentStatusID":"10","companyTruncated":"ANRS, Emerging Infectious Diseases \/ Merck & Co | European & Developing Countries Clinical Trials Partnership"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ATI-2173","moa":"||Hepatitis B virus Polymerase (HBV P)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Antios Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Antios Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antios Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"GordonMD Global Investments","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"ATI-2173","moa":"||Active site polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Antios Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Antios Therapeutics \/ GordonMD Global Investments","highestDevelopmentStatusID":"15","companyTruncated":"Antios Therapeutics \/ GordonMD Global Investments"},{"orgOrder":0,"company":"Enyo Pharma","sponsor":"Novotech | Syneos Health | Eurofins CDMO | Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Entecavir","moa":"||FXR","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enyo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Enyo Pharma \/ Novotech | Syneos Health | Eurofins CDMO | Parexel","highestDevelopmentStatusID":"8","companyTruncated":"Enyo Pharma \/ Novotech | Syneos Health | Eurofins CDMO | Parexel"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vebicorvir","moa":"||Core antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Assembly Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Assembly Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Arbutus Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vebicorvir","moa":"||Core antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Assembly Biosciences \/ Arbutus Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Assembly Biosciences \/ Arbutus Biopharma"},{"orgOrder":0,"company":"Public Health Foundation Enterprises","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Emtricitabine","moa":"||Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Public Health Foundation Enterprises","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Public Health Foundation Enterprises \/ Gilead Sciences","highestDevelopmentStatusID":"11","companyTruncated":"Public Health Foundation Enterprises \/ Gilead Sciences"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"ViiV Healthcare | Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"||Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ ViiV Healthcare | Viatris","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ ViiV Healthcare | Viatris"},{"orgOrder":0,"company":"University Hospital, Caen","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Doravirine","moa":"||Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University Hospital, Caen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"University Hospital, Caen \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital, Caen \/ Merck & Co"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"HIV Prevention Trials Network","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"||Structural capsid protein","graph1":"Undisclosed","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ HIV Prevention Trials Network","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ HIV Prevention Trials Network"},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ATI-2173","moa":"||Active site polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Antios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Antios Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antios Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Emtricitabine","moa":"||Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"||Structural capsid protein","graph1":"Undisclosed","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Antios Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"ATI-2173","moa":"||HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arbutus Biopharma \/ Antios Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Biopharma \/ Antios Therapeutics"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"JNJ-3989","moa":"||HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"HIV Prevention Trials Network | National Institute on Drug Abuse | National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"||Structural capsid protein","graph1":"Undisclosed","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gilead Sciences \/ HIV Prevention Trials Network | National Institute on Drug Abuse | National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ HIV Prevention Trials Network | National Institute on Drug Abuse | National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"||Structural capsid protein","graph1":"Undisclosed","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"JNJ-56136379","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Entecavir","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Entecavir Monohydrate","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Entecavir","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Entecavir","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tenofovir Disoproxil Fumarate","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vir Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vir Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Entecavir Monohydrate","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Entecavir","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"MERCK CANADA INC","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Doravirine","moa":"||Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Health Network, Toronto \/ MERCK CANADA INC","highestDevelopmentStatusID":"11","companyTruncated":"University Health Network, Toronto \/ MERCK CANADA INC"},{"orgOrder":0,"company":"University of North Carolina, Chapel Hill","sponsor":"Doris Duke Foundation | Universit\u00e9 Protestant au Congo | Abbott Laboratories | Albert Einstein College of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tenofovir Disoproxil Fumarate","moa":"||Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"University of North Carolina, Chapel Hill","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of North Carolina, Chapel Hill \/ Doris Duke Foundation | Universit\u00e9 Protestant au Congo | Abbott Laboratories | Albert Einstein College of Medicine","highestDevelopmentStatusID":"11","companyTruncated":"University of North Carolina, Chapel Hill \/ Doris Duke Foundation | Universit\u00e9 Protestant au Congo | Abbott Laboratories | Albert Einstein College of Medicine"},{"orgOrder":0,"company":"Prism Health North Texas","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Doravirine","moa":"||Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Prism Health North Texas","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prism Health North Texas \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Prism Health North Texas \/ Merck & Co"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tenofovir Disoproxil Fumarate","moa":"||Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Undisclosed","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"MRC\/UVRI and LSHTM Uganda Research Unit","sponsor":"King's College London | London School of Hygiene & Tropical Medicine | Africa Health Research Institute | Wits Health Consortium | University College, London | Ministry of Health, Uganda | Desmond Tutu HIV Foundation | Assistance Publique \u2013 H\u00f4pitaux de Pa","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tenofovir Disoproxil Fumarate","moa":"||Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"MRC\/UVRI and LSHTM Uganda Research Unit","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MRC\/UVRI and LSHTM Uganda Research Unit \/ King's College London | London School of Hygiene & Tropical Medicine | Africa Health Research Institute | Wits Health Consortium | University College, London | Ministry of Health, Uganda | Desmond Tutu HIV Foundation | Assistance Publique \u2013 H\u00f4pitaux de Pa","highestDevelopmentStatusID":"10","companyTruncated":"MRC\/UVRI and LSHTM Uganda Research Unit \/ King's College London | London School of Hygiene & Tropical Medicine | Africa Health Research Institute | Wits Health Consortium | University College, London | Ministry of Health, Uganda | Desmond Tutu HIV Foundation | Assistance Publique \u2013 H\u00f4pitaux de Pa"},{"orgOrder":0,"company":"University of Witwatersrand, South Africa","sponsor":"ViiV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Witwatersrand, South Africa","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"University of Witwatersrand, South Africa \/ ViiV Healthcare","highestDevelopmentStatusID":"10","companyTruncated":"University of Witwatersrand, South Africa \/ ViiV Healthcare"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Suspension, Extended Release","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"ViiV Healthcare | Bill & Melinda Gates Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ ViiV Healthcare | Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"10","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ ViiV Healthcare | Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Eastern Virginia Medical School","sponsor":"CONRAD | FHI 360 | United States Agency for International Development | Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Emtricitabine","moa":"||Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Undisclosed","graph2":"Phase II","graph3":"Eastern Virginia Medical School","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eastern Virginia Medical School \/ CONRAD | FHI 360 | United States Agency for International Development | Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Eastern Virginia Medical School \/ CONRAD | FHI 360 | United States Agency for International Development | Gilead Sciences"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Entecavir Monohydrate","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals for Tenofovir Disoproxil
Details :
Stride's Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Truvada Tablets, 200 mg/300 mg, of Gilead Sciences.
Sponsor :
King's College London | London School of Hygiene & Tropical Medicine | Africa Health Research Institute | Wits Health Consortium | University College, London | Ministry of Health, Uganda | Desmond Tutu HIV Foundation | Assistance Publique – Hôpitaux de Pa
Sponsor :
King's College London | London School of Hygiene & Tropical Medicine | Africa Health Research Institute | Wits Health Consortium | University College, London | Ministry of Health, Uganda | Desmond Tutu HIV Foundation | Assistance Publique – Hôpitaux de Pa
Reset All
Synergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.
